4GQQ image
Deposition Date 2012-08-23
Release Date 2012-10-24
Last Version Date 2024-11-27
Entry Detail
PDB ID:
4GQQ
Title:
Human pancreatic alpha-amylase with bound ethyl caffeate
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.35 Å
R-Value Free:
0.22
R-Value Work:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Pancreatic alpha-amylase
Gene (Uniprot):AMY2A
Chain IDs:A
Chain Length:496
Number of Molecules:1
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
PCA A GLN PYROGLUTAMIC ACID
Primary Citation
Order and disorder: differential structural impacts of myricetin and ethyl caffeate on human amylase, an antidiabetic target.
J.Med.Chem. 55 10177 10186 (2012)
PMID: 23050660 DOI: 10.1021/jm301273u

Abstact

The increasing prevalence of diabetes has accelerated the search for new drugs derived from natural sources. To define the functional features of two such families of compounds, the flavonols and the ethyl caffeates, we have determined the high-resolution structures of representative inhibitors in complex with human pancreatic α-amylase. Myricetin binds at the active site and interacts directly with the catalytic residues despite its bulky planar nature. Notably, it reduces the normal conformational flexibility of the adjacent substrate binding cleft. In contrast, bound ethyl caffeate acts by disordering precisely those polypeptide chain segments that make up the active site binding cleft. It also operates from binding sites far removed from the active site, a property not observed in any other class of human α-amylase inhibitor studied to date. Given the current inadequacy of drugs directed at diabetes, the use of optimized flavonols and ethyl caffeates may present an alternative therapeutic route.

Legend

Protein

Chemical

Disease

Primary Citation of related structures